Houba, Inc. - 16245 State Road

Houba abt Nabta was categorized under Research and Development Laboratories.

Fpund under the Indiana LLC records is:

1976 - Feb. 28 / Mar cc - Houba, Inc. of Indiana
George Kresck ,(Chairman/President)
Julia Kresck (secretary) and
Eric A Kresck Kresck
marged with Houba Inc. - Connecticut (10/30/1973) both appeared to have the same board of directors/officers by the records found.

? - 1989 - Dec 1 - George R. Krysek

HOUBA INC % HALSEY DRUG CO INC

1990s, Halsey Pharmaceuticals, headquartered in New York, bought the company

1993 - Houba subsidiary purchased a 25% equity interest in Penick in mid-1993. In addition, in September 1995, Houba purchased an 8.3% equity interest in Penick Pharmaceutical, Inc., which owns the other 75% of Penick. In May 1996, the Company advanced Penick approximately $250,000 in order to continue the supply of raw materials for the production of acetaminophen/oxycodone capsules.

1996 - Houba owns approximately 45,000 square feet of building space on approximately 30 acres of land in Culver, Indiana, which includes a 15,000 square foot manufacturing facility. This manufacturing facility houses separate plants for the production of Doxycycline raw materials, Doxycycline capsules and tablets and Biotin raw materials. In 1996, in conjunction with a settlement with two former employees, the Company acquired real property, improved by a residential property, in Culver, Indiana adjacent to the manufacturing facility. The Company became the lessor of the residential property upon closing of the acquisition. 1997 - During the period from May 1997 through July 1997, the Company borrowed approximately $3 million from Mylan Laboratories, Inc. pursuant to five unsecured, demand promissory notes. The advances made by Mylan Laboratories, Inc. were part of a proposed investment by Mylan Laboratories, Inc. in the Company, including the proposed purchase of the Company's Houba Indiana facility as well as a partial tender offer for the Company's common stock. The Company used the proceeds of these borrowings for working capital. The $3 million indebtedness relating to such advances remains outstanding and the Company anticipates negotiating with representatives of Mylan Laboratories, Inc. in an attempt to structure repayment terms acceptable to the Company.

2001 - December 31, 2001, the entire $17.5 million available under the Watson Term Loan had been advanced to the Company. The net proceeds from the term loan have, in large part, been used to upgrade and equip the API manufacturing facility of Houba, Inc....

2003 Dec 31 - Annual report section appling to Culver plant
In accordance with the restructuring of the its operations, the Company has transitioned to a single vertically integrated operations site located at its Houba, Inc. subsidiary in Culver, Indiana. The Company intends to implement the following strategy and perform relevant key activities primarily at the Culver Facility:
• Development of the Company's proprietary abuse deterrent formulation technology (the "ADF Technology") for use in orally administered opioid finished dosage products.
• - Manufacture and quality assurance release of clinical trial supplies of certain finished dosage form products utilizing the ADF Technology.
• - Evaluation of certain finished dosage products utilizing the ADF Technology in clinical trials.
• - Scale-up and manufacture of commercial quantities of certain products utilizing the ADF Technology for sale by the Company's licensees.
• - Research, development and scale up of the Company's novel Opioid Synthesis Technologies.
• - Prosecution of the Company's application to the DEA to receive a registration (the "Import Registration") to import Narcotic Raw Materials ("NRMs") for use in the production of opioid API's utilizing the Company's Opioid Synthesis Technologies
.
• - Negotiating and executing license and development agreements with strategic pharmaceutical company partners providing that such licensees will further develop certain finished dosage products utilizing the ADF Technology, file for regulatory approval with the FDA and other regulatory authorities and commercialize such products.

1998 - Trademark applications and grants for Houba Inc.

Mark Image: "DOXYCHEL"
Registration: 1532604
Serial: 73708424
Trademark: DOXYCHEL
Application Date: 1988-01-29
Company Registrations:

NCAGE Code 0N3U4 HOUBA INC
CAGE Code 0N3U4 HOUBA INC
SEC 0000816004 HOUBA INC

2007/2011 - Houba Inc. acquired by Acura Pharmaceuticals Inc

Acura has more than 35-year history in Culver
Jan 1 2013 - Jeff Kenny
The Acura Pharmaceuticals plant at 16235 State Road 17 in Culver hasn't always been known by that name. Many in the area will recall it as Houba, Inc., a title dating back to at least 1974.

According to John Gilkay, director of environmental, health and safety, and engineering at the Culver Acura facility, the company was started out of a garage attached to the house just south of Acura today, by George Krsek, who had purchased the rights to an antibiotic product called Doxycycline from a company in California.

Under Krsek, a PhD chemist who had worked on a variety of projects, the company expanded.

In the 1990s, Halsey Pharmaceuticals, headquartered in New York, bought the company, says Gilkay.

"In the mid to late `90s, they (Houba) experienced some environmental problems" he explains. "Over the next several years, those issues were resolved and many facility modifications were completed."

Houba was in the process of "negotiating and completing corrective actions when I joined the company in the fall of 2000," Gilkay says.

At that time, some of the environmental issues had been worked out while some still needed rectifying.

"When I came here, all of the facility activities revolved around the antibiotic manufacture. It was somewhat unique in that they did the front-end chemical manufacturing of the drug in one part of the facility and then turned that into tablets and capsules in another part of the facility.

They also conducted product testing, packaged and shipped Doxycycline products for a variety of customers."

Around 2003, the company had a regime change, with a new CEO who decided to discontinue manufacturing operations at the Culver facility and shut down a New York facility. About 85 percent of the Houba staff in Culver was laid off at that time, says Gilkay, and the focus shifted to creation and development of abuse deterrent products, such as Nexafed.

In conjunction with the change in operational focus, the Culver facility also changed its name from Houba, Inc. to Acura Pharmaceutical Technologies, Inc. Similarly, the publicly traded parent company, Halsey Pharmaceuticals, Inc. became Acura Pharmaceuticals, Inc., still publicly traded despite its small size.

Acura Pharmaceuticals proper has been in business since 2002, says CEO and president Bob Jones, and its corporate headquarters are in Palatine, Illinois, though Jones himself works from New Jersey, while a few in the company work from Atlanta.

In all, there are today just 15 members of the Acura company, eight of whom work in Culver. "So we're very heavily focused towards research and development in how we spend our money," Jones notes.

2013-2024 - Acura Pharmaceuticals, Inc.’s Andrew D. Reddick Research and Development Center on State Road 17; under Indiana LLC's still appears as Houba Inc. c/o Acura Pharmaceuticals, Inc.

---

Today is